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Abstract: Quercetin (Q) has rapid metabolism, which may make it worthwhile to focus on the
potential activity of its metabolites. Our aim was to evaluate the triglyceride-lowering effects
of Q metabolites in mature and pre-adipocytes, and to compare them to those induced by Q.
3T3-L1 mature and pre-adipocytes were treated with 0.1, 1 and 10 µM of Q, tamarixetin (TAM),
isorhamnetin (ISO), quercetin-3-O-glucuronide (3G), quercetin-3-O-sulfate (3S), as well as with 3S
and quercetin-4-O-sulfate (4S) mixture (3S+4S). Triglyceride (TG) content in both cell types, as well as
free fatty acid (FFA) and glycerol in the incubation medium of mature adipocytes were measured
spectrophotometrically. Gene expression was assessed by RT-PCR. In mature adipocytes, Q decreased
TG at 1 and 10 µM, 3S metabolite at 1 and 10 µM, and 3S+4S mixture at 10 µM. 3S treatment modified
the glucose uptake, and TG assembling, but not lipolysis or apoptosis. During differentiation, only
10 µM of ISO reduced TG content, as did Q at physiological doses. In conclusion, 3S metabolite but
not ISO, 3G, 4S and TAM metabolites can contribute to the in vivo delipidating effect of Q.
Keywords: Quercetin; metabolites; adipocytes; triglycerides
1. Introduction
Quercetin (Q) is a polyphenol classified as a flavonoid, found, mainly in glycoside form, in
a variety of foods including berries, onions and shallots, apples, tea and chocolate [1]. Some of its
metabolites, such as Isorhamnetin (ISO) and quercetin-3-O-glucuronide (3G), are also present in several
food sources [2]. It is estimated that the dietary intake of Q is 5–40 mg/day [3]. However, consumption
can reach 200–500 mg/day when fruits and vegetables are abundant in the diet, especially if they are
eaten with their skin [4].
Obesity, defined as excess fat accumulation in white adipose tissue, plays a key role as a regulator
of lipid storage and release. It can be developed by increasing adipocyte number (hyperplasia)
and/or size (hypertrophy) [5]. When hyperplasia takes place, there is a stimulation of pre-adipocyte
proliferation and further differentiation. This process, which promotes pre-adipocyte differentiation
into mature adipocytes is known as adipogenesis [6]. Nevertheless, this increase in adipocyte number
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does not necessarily promote obesity directly. Instead, during childhood growth, it determines the
lipid-storing capacity of adipose tissue and fat mass in adulthood [7].
For triglyceride synthesis and further storage, mature adipocytes need a source of fatty acids
and of glycerol-3-P. Fatty acids can be obtained from triglycerides circulating as lipoproteins, due to
the action of lipoprotein lipase (LPL), which can be synthesized de novo from Acetyl-CoA or can be
taken-up directly from circulation through specific transporters. Glycerol-3-P comes from glucose
metabolism, after glucose uptake from blood through the glucose transporter GLUT-4. These two
molecules are assembled into triglycerides in a process catalyzed by several enzymes. TG stored in
adipose tissue can be mobilized in the process known as lipolysis, mediated by three lipases, which
implies a breakdown of stored triglycerides and subsequent release of fatty acids and glycerol.
Q has recently been shown to be a potential body fat-lowering molecule. Its positive impact on
lipolysis, apoptosis, fatty acid uptake, inhibition of adipogenesis and reduction of lipogenesis has
been proposed as its mechanism of action [8–12]. In addition, it seems that its effect on white adipose
tissue is accompanied by muscle and liver mitochondrial biogenesis and by improved glycaemic
control among other effects, resulting in it being a multi-target flavonoid for body fat reduction [13,14].
Not only abundant cell culture experiments [8,10,15,16], but also animal studies have confirmed its
usefulness in body fat reduction, mostly in obese animals [17–22]. However, studies in humans remain
scarce [19,23–25]. A matter of concern in the use of Q as a bioactive molecule is its rapid metabolism,
and thus its low bioavailability. Chen et al. [26] determined that 60% of total quercetin ingested by
rats was absorbed, and 55.8% of this absorbed amount was metabolized by the gut and 1.8% by the
liver. After ingestion, Q is transformed into an aglycone form in the small intestine, that in turn is
further metabolized by glucuronidation, sulfatation and methylation reactions [27]. As a result, only
a reduced amount of Q and considerable amounts of metabolites reach the bloodstream. According
to the literature, the most predominant metabolites in plasma are ISO, tamarixetin (TAM), 3G and
quercetin-3-O-sulfate (3S) [28–31] (Figure 1), with glucuronide metabolites being those that appear in
higher concentrations and sulfate and methylated those that appear in lower concentrations [32–34].
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  2 of 13 
 
differentiation into mature adipocytes is known as adipogenesis [6]. Nevertheless, this increase in 
adipocyte number does not necessarily promote obesity directly. Instead, during childhood growth, 
it determines the lipid-storing capacity of adipose tissue and fat mass in adulthood [7]. 
For triglyceride synthesis and further storage, mature adipocytes need a source of fatty acids 
and of glycerol-3-P. Fatty acids can be obtained from triglycerides circulating as lipoproteins, due to 
the action of lipoprotein lipase (LPL), which can be synthesized de novo from Acetyl-CoA or can be 
taken-up directly from circulation through specific transporters. Glycerol-3-P comes from glucose 
metabolism, after glucose uptake from blood through the glucose transporter GLUT-4. These two 
molecules are assembled into triglycerides in a process catalyzed by several enzymes. TG stored in 
adipose tissue can be mobilized in the process known as lipolysis, mediated by three lipases, which 
implies a breakdown of stored triglycerides and subsequent release of fatty acids and glycerol. 
Q has recently been shown to be a potential body fat-lowering molecule. Its positive impact on 
lipolysis, apoptosis, fatty acid uptake, inhibition of adipogenesis and reduction of lipogenesis has 
been proposed as its mechanism of action [8–12]. In addition, it seems that its effect on white adipose 
tissue is accompanied by muscle and liver mitochondrial biogenesis and by improved glycaemic 
control among other effects, resulting in it being a multi-target flavonoid for body fat reduction 
[13,14]. Not only abundant cell culture experiments [8,10,15,16], but also animal studies have 
confirmed its usefulness in body fat reduction, mostly in obese animals [17–22]. However, studies in 
humans remain scarce [19,23–25]. A matter of concern in the use of Q as a bioactive molecule is its 
rapid metabolism, and thus its low bioavailability. Chen et al. [26] determined that 60% of total 
quercetin ingested by rats was absorbed, and 55.8% of this absorbed amount was metabolized by the 
gut and 1.8% by the liver. After ingestion, Q is transformed into an aglycone form in the small 
intestine, that in turn is further metabolized by glucuronidation, sulfatation and methylation 
reactions [27]. As a result, only a reduced amount of Q and considerable amounts of metabolites reach 
the bloodstream. According to the literature, the most predominant metabolites in plasma are ISO, 
tamarixetin(TAM), 3G and quercetin-3-O-sulfate (3S) [28–31] (Figure 1), with glucuronide 
metabolites being those that appear in higher concentrations and sulfate and methylated those that 
appear in lower concentrations [32–34]. 
 
Figure 1. Chemical structures of Q and its metabolites. 
Bearing this in mind, it is not possible to be sure that the fat-lowering properties of Q observed 
in in vivo experiments are exclusively attributable to Q. The potential activity of its metabolites 
Figure 1. Chemical structures of Q and its metabolites.
Bearing this in mind, it is not possible to be sure that the fat-lowering properties of Q observed in
in vivo experiments are exclusively attributable to Q. The potential activity of its metabolites should
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not be discarded. Data concerning this issue in adipocytes are scarce so far [35–37]. Studies carried out
with these molecules in A549 lung cancer cells revealed that Q metabolites could have similar positive
effects to those of Q on cell invasion and migration [38].
Considering all these issues, in the present study we wanted to assess whether Q and/or its
metabolites are responsible for its beneficial effects in terms of delipidating molecule. For this purpose,
the triglyceride-lowering effect of methylated metabolites TAM and ISO, 3G, 3S and a mixture (3S+4S)
of 3S and quercetin-4-O-sulfate (4S) in pre-adipocytes and mature adipocytes was evaluated and
compared to that induced by Q.
2. Results and Discussion
In order to address the challenge of determining delipidating capacity of each Q metabolite,
several approaches with isolated TAM, ISO, 3G, 3S, and 3S+4S mixture dissolved in ethanol were
performed in mature and maturing murine adipocytes. With regard to cell treatment, two aspects
must be pointed out. First, the final concentration of ethanol per adipocyte was well below 0.1%, a
previously reported non-toxic concentration [39–42]. Secondly, the assays were conducted with doses
lower than those commonly used in cell culture experiments (0.1, 1 and 10 µM). One of the reasons
for choosing these doses is related to the prevention of cell integrity, because 10 µM of ISO and 3G
was declared as safe in Raw 2647 cells, but toxic effects were observed for both molecules at 25 and
100 µM, respectively [43]. Moreover, in vivo supplementation studies are commonly carried out by
using doses of Q that lead to plasma Q and Q metabolite concentrations in the range of nanomolar
and micromolar [44,45]. In addition, in previous studies from our laboratory, doses of Q in the range
of serum concentrations (≤10 µM) were tested in adipocytes, revealing a dose-dependent effect on
triglyceride (TG) reduction in pre-adipocytes [12].
Apart from commercially available metabolites TAM, ISO and 3G, hemisynthetized quercetin
sulfate mixture (3S+4S) and 3S were also used for the present study. Supplementary Figure S1 shows
the HPLC chromatograms recorded at 370 nm with the two obtained fractions. In the case of the
mixture, 4S and 3S represented 33.4% and 62.5% of the recorded peak areas, respectively.
No significant changes in mature adipocyte TG content were observed when these cells were
incubated with the lowest dose (0.1 µM) of the molecules studied. At a dose of 1 µM, only the 3S
metabolite, among all the molecules tested, reduced TG content. Finally, at 10 µM, Q, 3S+4S and 3S
significantly reduced TG content in adipocytes (21%, 20% and 32%, respectively). By contrast, 3G, ISO
and TAM were ineffective (Figure 2). Similar results were reported by Lee et al. with ISO treatment in
mature adipocytes [35].
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Figure 2. Effects of 0.1, 1 and 10 µM of quercetin (Q), isorhamnetin (ISO), tamarixetin (TAM),
quercetin-3-O-glucuronide (3G), quercetin-3-O-sulfate (3S), as well as 3S and quercetin-4-O-sulfate (4S)
mixture (3S+4S) on triacylglycerol content of 3T3-L1 mature adipocytes treated for 24 h. Values are
means ± SEM. Comparison between each flavonoid dose and the control was analyzed by Student’s
t-test. The asterisks represent differences versus the controls (* p < 0.05; *** p < 0.001).
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In order to explain the TG reduction observed, gene expression of mature adipocyte-specific
genes was analyzed at the dose of 10 µM. We chose the highest dose to carry out this analysis because
this was the active one for a great number of the molecules analyzed. Treatment with 10 µM of 3S
significantly decreased and 3S+4S tended to reduce lipoprotein lipase (lpl) expression (Figure 3A,B).
Evidence confirmed that adipocyte-derived LPL is required for efficient fatty acid uptake and further
TG storage in 3T3-L1 adipocytes [46]. It is true that LPL is not determining in in vitro TG accumulation.
However, the reduction observed could suggest a positive mechanism of action in in vivo situation.
With regard to lipolysis, treatment with 3S+4S tended to reduce adipose triglyceride lipase (atgl) expression
(p = 0.09) in mature adipocytes and thus, in order to clarify whether this change could result in changes
in this metabolic pathway, glycerol and FFA release were measured (Supplementary Figure S2). Given
that, as previously reported with Q [12], no changes were observed and consequently, it seems that
lipolysis is not involved in TG reduction. On the other hand, even though further analysis is needed in
order to confirm this fact, it can be proposed that 3S metabolite, alone or in combination with 4S, could
act reducing fatty acid uptake.
According to research conducted with adipose tissue explants from lean, overweight, obese
and morbidly obese subjects, body fat mass increase is associated with CASP3 and P53 expression
elevation and BCL2 expression reduction [47]. Thus, as the apoptotic pathway is related to adipose
tissue homeostasis, the potential involvement of 3S metabolite in apoptosis was studied. It promoted
remarkably elevated levels of trp53, a gene that codifies tumor suppressor p53 protein. While p53 is
linked with apoptosis, it has many other roles including cell-cycle arrest, DNA repair or senescence [48].
Due to this fact, other apoptosis-related genes such as caspase 3 (cas3) and the anti-apoptotic gene
bcl2 were assessed (Figure 3A). The expression of both genes revealed apoptosis reduction, instead of
promotion with 3S treatment (bcl2 elevation and cas3 decrease). Thus, apoptosis does not represent a
mechanism of action for 3S metabolite in mature adipocytes. In fact, when 4S was included there was
no effect on apoptotic genes. Although the mixture 3S+4S raised the expression of trp53, no changes
were observed in cas3 or bcl2 genes (Figure 3B).
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Figure 3. Effects of quercetin-3-O-sulfate (3S) (A) an quercetin-3-O-sulfate and quercetin-4-O-sulfate
mixture (3S+4S) (B) at a dose of 10 µM on the expression of atgl, hsl, lpl, fasn, dgat1, dgat2, glut4, trp53,
cas3 and bcl2 in 3T3-L1 mature adipocytes treated for 24 h. Values are means ± SEM. Comparison of
3S or3S+4S and the control for each gene expression was analyzed by Student’s t-test. The asterisks
represent differences versus the controls (* p < 0.05; ** p < 0.01; *** p < 0.001).
Apart from fatty acid uptake, lipolysis and apoptosis, lipogenesis is another crucial metabolic
process involved in fat storage. Uptaken fatty acids or new synthesized ones must be assembled
with glycerol in order to accumulate triglyceride inside the adipocyte. As a result, facilitated glucose
transporter member 4 (glut4), as well as diacylglycerol o-acyltransferase (dgat), genes involved in glucose
uptake and TG assembly, can be considered limiting genes for TG synthesis. 3S, but not 3S+4S, reduce
glut4, dgat1 and dgat2 gene expression (Figure 3A,B). By contrast, fatty aci synthase (fa n) related to de
novo lipogenesis was not modified by the analyzed molecules. These results suggest that the synthesis
of fatty acids is not affected by Q metabolite treatment and TG assembly is reduced.
As far as we know this is the first study to reveal the potential effectiveness of Q metabolites in
mature adipocytes, postulating that glucose uptake and TG assembling are mechanisms that could
justify the TG reduction observed in mature adipocyte after 3S treatment. Consequently, the effects on
body fat observed in an mals a ter Q administration would be due not only to the parent compound
but also to this metabolite. It is important to highlight that the addition of 4S metabolite to 3S did not
confer any additional effect. In fact, the expression of evaluated genes revealed a decrease in their
impact (Figure 3B). These results suggest that the TG-lowering effect can be attributed exclusively to
3S metabolite, and that the addition of 4S results in a dilution of the effective molecule.
It has been described that adipocyte turnover rate for lean and obese humans is around 10% [7].
As mature adipocytes do not have the ability to divide, adipocyt precursors with this capacity must
exist in adipose tissue. For this reason, in addition to mature adipocyte analysis, the effects of Q
metabolites on pre-adipocytes were also assessed in the present study. ISO has been the most studied
of all the Q metabolites in maturing adipocytes. It has been demonstrated that this metabolite reduces
TG accumulation, with 10 µM the most effective dose in 3T3-L1 and human adipose tissue-derived
stems cells [35,49]. Zhang et al. also reported similar results in 3T3-L1 pre-adipocytes, 12.5 µM being
the lowest effective d se [37]. In good accordance with these studies, a significant reduction after
10 µM ISO treatment was observed in maturing pre-adipocytes in the present work. Nevertheless,
none of the remaining Q metabolites was able to reduce TG at the doses of 1 or 10 µM, as Q did
(Figure 4).
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Figure 4. Effects of 0.1, 1 and 10 µM of quercetin (Q), isorhamnetin (ISO), tamarixetin (TAM),
quercetin-3-O-glucuronide (3G), quercetin-3-O-sulfate (3S), as well as 3S and quercetin-4-O-sulfate (4S)
mixture (3S+4S) on triacylglycerol content of 3T3-L1 maturing pre-adipocytes treated from day 0 to day
8. Values are means ± SEM. Comparison between each flavonoid dose and the control was analyzed
by Student’s t-test. The asterisks represent differences v rsus the controls (* p < 0.05; *** p < 0.001).
With regard to the mechanisms of action for ISO, Lee et al. [35] demonstrated that nine days of
treatment in maturing 3T3-L1 pre-adipocytes with 50 µM reduced adipogenesis through the inhibition
of peroxisome proliferator-activated receptor γ (pparγ) and CCAAT/enhancer-binding protein α (cebpα). In our
cell cultures, the dose of 10 µM tended to decrease pparγ gene expression (p = 0.06), but not that of
cebpα, cebpβ o sterol regulatory element-binding factor (srebf1) (Figure 5). By comp ring both studies, it is
clear that higher doses promote greater impact on adipogenesis inhibition. This conclusion was also
reached by Zhang et al. [37], who revealed that ISO treatment decreased adipocyte differentiation at
a concentration of 12.5 µM and totally blocked this process at 50 µM. Likewise, they proposed the
differentiation stage as a limiting step for ISO effect. According to their data, the inhibitory effect on
adipogenesis was less prominent when ISO was added at the latter stages of differentiation. Moreover,
they indic ted that ISO may control the early differentiation stage by inhibiting the trans ctivation of
pparγ. In the present research, we treated 3T3-L1 pre-adipocytes with ISO throughout the adipogenic
process (eight days). Therefore, the weak effect on pparγ expression observed could be due not only to
the low dose but also to the influence of the differentiating stage.
Much as took place with 3S metabolite treatment of mature adipocytes, the expression of trp53
was increased after ISO treatment of differentiating pre-adipocytes, but a diminution of mRNA levels
of the dea h repressor bcl2 was obse ved (Figure 5). Furthermore, ISO treatm nt did not promote
any change in cas3 expression. These results reveal that the apoptosis pathway was not completely
activated by ISO treatment, probably due to the low dose used. Mirroring mature adipocyte gene
analysis, the expression of dagt1, dgat2, and glut4 was also evaluated. With the exception of glut4, no
changes in the genes mentioned were detected (Figure 5). Therefore, glucose uptake and TG assembly
did not justify the observed delipidating effect of ISO.
In spite of the significant effects observed in the expression of several genes the only Q metabolite
to induce a significant reduction in pre-adipocyte TG content was ISO, but at 10 µM, a dose higher
than that found in serum when animals are treated with Q. Bearing this fact in mind, the involvement
of Q metabolites in the anti-obesity effect of this phenolic compound cannot be proposed.
Int. J. Mol. Sci. 2019, 20, 264 7 of 13
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 13 
 
 
Figure 4. Effects of 0.1, 1 and 10 µM of quercetin (Q), isorhamnetin (ISO), tamarixetin (TAM), 
quercetin-3-O-glucuronide (3G), quercetin-3-O-sulfate (3S), as well as 3S and quercetin-4-O-sulfate 
(4S) mixture (3S+4S) on triacylglycerol content of 3T3-L1 maturing pre-adipocytes treated from day 0 
to day 8. Values are means ± SEM. Comparison between each flavonoid dose and the control was 
analyzed by Student’s t-test. The asterisks represent differences versus the controls (* p < 0.05; *** p < 
0.001). 
With regard to the mechanisms of action for ISO, Lee et al. [35] demonstrated that nine days of 
treatment in maturing 3T3-L1 pre-adipocytes with 50 µM reduced adipogenesis through the 
inhibition of peroxisome proliferator-activated receptor γ (pparγ) and CCAAT/enhancer-binding protein α 
(cebpα). In our cell cultures, the dose of 10 µM tended to decrease pparγ gene expression (p = 0.06), 
but not that of cebpα, cebpβ or sterol regulatory element-binding factor (srebf1) (Figure 5). By comparing 
both studies, it is clear that higher doses promote greater impact on adipogenesis inhibition. This 
conclusion was also reached by Zhang et al. [37], who revealed that ISO treatment decreased 
adipocyte differentiation at a concentration of 12.5 µM and totally blocked this process at 50 µM. 
Likewise, they proposed the differentiation stage as a limiting step for ISO effect. According to their 
data, the inhibitory effect on adipogenesis was less prominent when ISO was added at the latter 
stages of differentiation. Moreover, they indicated that ISO may control the early differentiation stage 
by inhibiting the transactivation of pparγ. In the present research, we treated 3T3-L1 pre-adipocytes 
with ISO throughout the adipogenic process (eight days). Therefore, the weak effect on pparγ 
expression observed could be due not only to the low dose but also to the influence of the 
differentiating stage. 
 
Figure 5. Effects of 10 µM of isorhamnetin (ISO) on the expression of cebpβ, srebf1, pparγ, cebpα, dgat1, 
dgat2, glut4, trp53, cas3 and bcl2 in 3T3-L1 adipocytes treated for from day 0 to day 8. Values are means 
Figure 5. Effects of 10 µM of isorhamnetin (ISO) on the expression of cebpβ, srebf1, pparγ, cebpα, dgat1,
dgat2, glut4, trp53, cas3 and bcl2 in 3T3-L1 adipocytes treated for from day 0 to day 8. Values are
means ± SEM. Comparison between ISO and the control for each gene expression was analyzed by
Student’s t-test. The asterisks represent differences versus the control (* p < 0.05).
3. Materials and Methods
3.1. Reagents
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from GIBCO (BRL Life Technologies,
Grand Island, NY, USA). Q was purchased from Sigma (St. Louis, MO, USA) and ISO, TAM, and 3G
from Extrasynthese (Genay, France). TG were quantified by Infinity Triglycerides reagent (Thermo
Electron Corporation, Rockford, IL, USA) and protein concentrations of cell extracts were measured with
bicinchoninic acid (BCA) reagent (Thermo Scientific, Rockford, IL, USA). Commercial kits for analyzing
FFA and free glycerol were supplied by Roche and Sigma respectively (Free Fatty Acids, Half Micro Test,
Roche, Basilea, Sweden and F6428, Sigma, St. Louis, MO, USA).
3.2. Synthesis of Quercetin-3-O-Sulfate and Quercetin-4-O-Sulfate Metabolites
3.2.1. Synthesis of Quercetin Sulfates
Quercetin sulfates were synthesized as described by Dueñas et al. [50]. Dry pyridine was added to
quercetin (500 mg) to remove possible water associated with quercetin. Pyridine was rotary evaporated,
and the dry compound was dissolved in dioxane (50 mL) and allowed to react in a water bath (40 ◦C)
for 90 min with a 10-fold molar excess of sulfur trioxide-N-triethylamine complex under nitrogen to
avoid contact with air. Products of sulfation precipitated out and stuck to the glass. Dioxane was
decanted, and the precipitate was redissolved in 10% methanol in water. The mixtures of quercetin
sulfates were fractioned on a Sephadex LH-20 column (350 mm× 30 mm), successively eluted with 10%
aqueous ethanol (500 mL) and 20% aqueous ethanol (500 mL). The fractions containing monosulfates
were collected, concentrated to dryness under vacuum, redissolved in ultrapure water, and analyzed
by high-performance liquid chromatography with diode array and mass spectrometry detection
(HPLC-DAD-MS).
3.2.2. HPLC-DAD-MS Analyses
Analyses were carried out with a Hewlett-Packard 1100 chromatograph (Agilent Technologies,
Waldbronn, Germany) with a quaternary pump and a DAD coupled to a HP Chem Station (revision
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A.05.04) data-processing station. Separation was achieved on an Agilent Poroshell 120 EC-C18 column
(2.7 µm, 150 mm × 4.6 mm) thermostatted at 35 ◦C. Solvents used were (A) 0.1% TFA in water
and (B) acetonitrile and the elution gradient was from 10 to 15% B for 5 min, from 15 to 25% B for
5 min, from 25 to 35% B over 10 min, from 35 to 50% B over 10 min, isocratic 50% B for 10 min, and
re-equilibration of the column, at a flow rate of 0.5 mL/min. Double online detection was carried out
in the DAD using 250 and 370 nm as preferred wavelengths and in a mass spectrometer connected to
the HPLC system via the DAD cell outlet. MS detection was performed in a Finnigan LCQ detector
(Thermoquest, San Jose, CA, USA) equipped with an ESI source and an ion-trap mass analyzer, which
were controlled by the LCQ Xcalibur software. Both the auxiliary and sheath gases were nitrogen at
flow rates of 20 and 80 L/min, respectively. The source voltage was 4.5 kV; the capillary voltage was
11 V; and the capillary temperature was 220 ◦C. Spectra were recorded in negative-ion mode between
m/z 150 and 2000. The MS detector was programmed to perform a series of two consecutive scans: a
full scan and a MS-MS scan of the most abundant ion in the first scan, using a normalized collision
energy of 45%.
3.2.3. Identification and Quantification of Quercetin Sulfates
Chemical hemisynthesis of the quercetin sulfates was performed as described by Dueñas et al. [50].
The complex mixture of products obtained was fractionated on a Sephadex LH-20 column to separate
monosulfates from other products (quercetin and quercetin disulfates). Further fractionation by
semipreparative HPLC obtained pure quercetin sulfate and a mixture with two quercetin sulfates that
were freeze dried for further use.
Chromatograms peaks showed a pseudomolecular ion [M-H]- at m/z 381 that released a unique
fragment at m/z 301 (−80 amu, loss of a sulfate moiety), corresponding to quercetin. The peaks were
identified as quercetin 4’-O-sulfate (peak 1) and quercetin 3’-O-sulfate (peak 2) based on their comparison
with compounds previously synthesized and fully identified by NMR [50]. The chromatographic purity
of the compounds was calculated to be higher than 96% from the area of the peaks obtained in HPLC
chromatograms recorded at 370 and 250 nm.
3.3. Experimental Design
3T3-L1 pre-adipocytes, supplied by American Type Culture Collection (Manassas, VA, USA),
were cultured in DMEM containing 10% fetal calf serum (FCS). Two days after confluence (day
0), cells were stimulated to differentiate with DMEM containing 10% FCS, 10 µg/mL insulin,
0.5 mM isobutylmethylxanthine, and 1 µM of dexamethasone for two days. From day four onward,
the differentiation medium was replaced by FBS/DMEM medium (10%) containing 0.2 µg/mL insulin.
This medium was changed every two days until cells were harvested. All media contained 1%
Penicillin/Streptomycin (10,000 U/mL), and the media for differentiation and maturation contained
1% (v/v) of Biotin and Pantothenic Acid. Cells were maintained at 37 ◦C in a humidified 5%
CO2 atmosphere.
3.4. Cell Treatment
For the treatment of mature adipocytes, cells grown in 6-well plates were incubated with Q, ISO,
TAM, 3G, 3S and 3S+4S at 0.1, 1 and 10 µM (diluted in 95% ethanol) on day 12 after differentiation,
because at that day >90% of cells developed mature with visible lipid droplets. In the case of the
control group, the same volume of the vehicle (ethanol 95%) was used. Vehicle was diluted 1000-fold in
each well, reaching a final concentration of 0.095%. After 24 h, the supernatant was collected and cells
were used for TG determination, quantification of glycerol and FFA in the media and RNA extraction.
Each experiment was performed three times.
For the treatment of maturing pre-adipocytes, cells grown in 6-well plates were incubated with
Q, ISO, TAM, 3G, 3S and 3S+4S at 0.1, 1 and 10 µM (diluted in 95% ethanol) during differentiation.
In the case of the control group, the same volume of the vehicle (ethanol 95%) was used. Media
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containing, or not, molecules were changed every two days: on day 0, day 2, day 4, and day 6. On day
8, the supernatant was collected and cells were used for TG determination, RNA extraction and protein
extraction. Each experiment was performed three times.
3.5. Measurement of Triacylglycerol Content
After treatment, the medium was removed and cell extracts were used for TG determination.
Maturing pre-adipocytes and mature adipocytes were washed extensively with phosphate-buffered
saline and incubated three times with 800 µL of hexane/isopropanol (2:1). The total volume was then
evaporated by vacuumed centrifugation and the pellet was resuspended in 200 µL Triton X-100 in
1% distilled water. Afterwards, TGs were disrupted by sonication and the content was measured by
means of a commercial kit. For protein determinations, cells were lysed in 0.3N NaOH, 0.1% SDS.
Protein measurements were performed using the BCA reagent. TG content values were obtained as
mg triacylglycerols/mg protein and converted into arbitrary units.
3.6. RNA Extraction and RT-PCR
RNA samples from cells treated were extracted using Trizol (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. After RNA purity verification, samples were then treated
with DNase I kit (Applied Biosystems, Foster city, CA, USA) to remove any contamination with genomic
DNA. 1.5 µg of total RNA of each sample was reverse-transcribed to first-strand complementary DNA
(cDNA) using iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA).
Relative atgl, hsl, lpl, fasn, glut4, dgat1, dgat2, bcl2, trp53 and cas3 mRNA levels in mature adipocytes
and relative cebpα and cebpβ, srebf1, pparγ, glut4, dgat1, dgat2, bcl2, trp53 and cas3 mRNA levels in
maturing pre-adipocytes were quantified using Real-Time PCR with an iCyclerTM - MyiQTM Real
Time PCR Detection System (BioRad, Hercules, CA, USA). For atgl, hsl, lpl, fasn, cebpβ, srebf1 and
bcl2 SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) was used. The upstream
and downstream primers and probe (TibMolbiol, Berlin, Germany, Eurogentec, Liège, Belgium and
Metabion, Munich, Germany) are listed in Table 1. Cebpα, pparγ, glut4, dgat1, dgat2, trp53, and cas3 were
measured by TaqMan® Gene Expression Assays (Mm00514283_s1, Mm00440940_m1, Mm01731290_g1,
Mm00436615_m1, Mm00515643_m1, Mm499536_m1, Mm01195085_m1 and Mm02619580_g1) and
TaqMan® Fast Advanced Master Mix (Applied Biosystems, Foster City, CA, USA). RT-PCR parameters
used were those defined by manufacturer’s. β-actin mRNA levels were similarly measured and served
as the reference gene.
Table 1. Primers for PCR amplification of each studied gene.
Gene Sense Primer Anti-Sense Primer Annealing ta (◦C)
atgl 5′-GAGCTTCGCGTCACCAAC-3′ 5′-CACATCTCTCGGAGGACCA-3′ 60.0
hsl 5′-GGTGACACTCGCAGAAGACAATA-3′ 5′-GCCGCCGTGCTGTCTCT-3′ 60.0
lpl 5′-CAGCTGGGCCTAACTTTGAG-3′ 5′-CCTCTCTGCAATCACACGAA-3′ 61.5
fasn 5′-AGCCCCTCAAGTGCACAGTG-3′ 5′-TGCCAATGTGTTTTCCCTGA-3′ 60.0
β-actin 5′-ACGAGGCCCAGAGCAAGAG-3′ 5′ -GGTGTGGTGCCAGATCTTCTC-3′ 60.0
srebf1 5´- GCTGTTGGCATCCTGCTATC-3′ 5′-TAGCTGGAAGTGACGGTGGT-3′ 60.0
cebpβ 5′-CAAGCTGAGCGACGAGTACA-3′ 5′-CAGCTGCTCCACCTTCTTCT-3′ 67.5
bcl2 5′-AGTACCTGAACCGGCATCTG-3′ 5′-GGGGCCATATAGTTCCACAAA-3′ 60.0
atgl = adipose triglyceride lipase; hsl = hormone sensitive lipase; lpl = lipoprotein lipase; fasn= fatty acid synthase;
srebf1 = sterol regulatory element-binding factor 1; cebpβ = CCAAT-enhancer- binding protein β; bcl2 = B cell
leukemia/lymphoma 2.
All gene expression results were expressed as fold changes of threshold cycle (Ct) value relative
to controls using the 2−∆∆Ct method [51].
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3.7. Measurements of Glycerol and Free Fatty Acids in the Media
After treatment in mature adipocytes, aliquots of the medium treated with 10 µM of 3S+4S
were removed and analyzed for glycerol and FFA quantification by means of commercial kits
(see Reagents paragraph).
3.8. Statistical Analysis
Results are presented as mean ± standard error of the mean (SEM). Statistical analysis was
performed using SPSS 24.0 (SPSS Inc., Chicago, IL, USA). After confirming the normal distribution
of variables using Shapiro-Wilks normality test, each flavonoid dose effect against the control was
checked by Student’s t test. Statistical significance was set-up at the p < 0.05 level.
4. Conclusions
The results obtained in the present study demonstrate that 3S metabolite may contribute to the
delipidating effect of Q by reducing glucose uptake and TG assembling in mature adipocytes. ISO
metabolite diminished TG accumulation in pre-adipocytes, but at a concentration of 10 µM, which is
higher than that found in plasma from animals treated with Q. Consequently, its contribution to the
effect of Q should be discarded, as well as that of 3G, 4S and TAM.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/2/
264/s1.
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Abbreviations
3G quercetin-3-O-glucuronide
3S quercetin-3-O-sulfate
4S quercetin-4-O-sulfate
atgl adipose triglyceride lipase
bcl2 B cell leukemia/lymphoma 2
cas3 caspase 3
cebpα CCAAT-enhancer-binding protein α
cebpβ CCAAT-enhancer-binding protein β
dgat1 diacylglycerol O-acyltransferase 1
dgat2 diacylglycerol O-acyltransferase 2
DMEM Dulbecco’s modified Eagle’s medium
fasn fatty acid synthase
glut4 facilitated glucose transporter member 4
FCS fetal calf serum
FFA free fatty acid
hsl hormone sensitive lipase
ISO isorhamnetin
lpl lipoprotein lipase
pparγ peroxisome proliferator-activated receptor γ
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Q quercetin
srebf1 sterol regulatory element-binding factor 1
TAM tamarixetin
TG triacylglycerol
trp53 transformation related protein 53
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